[Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
Ikeda
K
K
Kumada
H
H
Arase
Y
Y
Chayama
K
K
Gunji
T
T
Yoshiba
A
A
Irimoto
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001201:Ascites / Q000139:chemically induced; D001927:Brain Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D005641:Tegafur / Q000009:adverse effects* / Q000097:blood; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects
D005641:Tegafur; D014498:Uracil